The Medicines Company Profile (NASDAQ:MDCO)

Analyst Ratings

Consensus Ratings for The Medicines (NASDAQ:MDCO) (?)
Ratings Breakdown: 3 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Buy (Score: 2.73)
Consensus Price Target: $48.75 (25.35% upside)

Analysts' Ratings History for The Medicines (NASDAQ:MDCO)
Show:
DateFirmActionRatingPrice TargetActions
7/27/2016GuggenheimBoost Price TargetBuy$45.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/19/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Bank of America Corp.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Jefferies GroupReiterated RatingBuy$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Chardan CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2016Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Piper Jaffray Cos.Reiterated RatingNeutral$28.00 -> $31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/31/2015Citigroup Inc.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2015MizuhoUpgradeNeutral -> Buy$28.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/20/2014Credit Suisse Group AGUpgradeNeutral -> Outperform$27.00 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for The Medicines (NASDAQ:MDCO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/27/2016        
7/27/2016Q216($1.16)($0.62)$41.93 million$54.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2016Q116($0.89)($1.03)$48.96 million$50.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2016Q415($1.54)($0.88)$64.11 million$67.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.88)($0.82)$68.58 million$72.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2015Q215($0.20)($0.65)$122.58 million$90.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115($0.68)($0.02)$138.78 million$126.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2015Q414($0.82)$0.20$191.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/22/2014Q314($0.12)$0.18$188.30 million$172.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2014Q214($0.02)($0.08)$183.75 million$183.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/23/2014Q114($0.07)($0.08)$175.60 million$177.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2014Q413$0.11$0.26$182.60 million$185.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/23/2013Q313$0.24$0.47$173.86 million$173.45 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/24/2013Q2 2013$0.33$0.50$168.70 million$172.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2013Q1 2013($0.26)$0.31$152.63 million$155.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/20/2013Q4 2012$0.28$0.38$146.09 million$159.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2012$0.39$0.40ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2012$0.22$0.46ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/25/2012$0.14$0.27ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/22/2012$0.24$0.52ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/26/2011$0.20$0.17ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/27/2011$0.31$0.21ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/27/2011$0.40$0.45ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/16/2011$0.24$0.30ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for The Medicines (NASDAQ:MDCO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.00)($0.76)($0.85)
Q2 20165($1.39)($0.74)($1.10)
Q3 20165($1.40)($0.76)($1.09)
Q4 20165($1.46)($0.77)($1.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for The Medicines (NASDAQ:MDCO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for The Medicines (NASDAQ:MDCO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/11/2016Hiroaki ShigetaDirectorSell3,849$38.50$148,186.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2016Christopher T CoxEVPBuy45,985$37.90$1,742,831.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2016Christopher T CoxEVPBuy53,340$37.55$2,002,917.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Melvin K SpigelmanDirectorSell15,000$37.00$555,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Clive MeanwellCEOSell10,000$35.00$350,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016William CrouseDirectorSell15,000$35.15$527,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2016Elizabeth H S WyattDirectorSell15,000$34.07$511,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Fredric N EshelmanDirectorBuy300,000$33.68$10,104,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016Armin M KesslerDirectorSell8,100$34.82$282,042.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2015Robert G. SavageDirectorSell5,000$39.34$196,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Glenn SblendorioCFOSell25,000$42.00$1,050,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Clive MeanwellCEOSell49,998$39.36$1,967,921.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Glenn SblendorioCFOSell114,495$39.75$4,551,176.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Melvin K. SpigelmanDirectorSell20,000$40.50$810,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015William Bernard O'connorSVPSell35,451$40.00$1,418,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Clive MeanwellCEOSell16,667$28.39$473,176.13View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2015Glenn SblendorioCFOSell3,305$32.00$105,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Hiroaki ShigetaDirectorSell7,500$28.99$217,425.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Robert G SavageDirectorSell15,000$26.78$401,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2015William Bernard O'connorSVPSell1,281$30.00$38,430.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Clive MeanwellCEOSell16,667$27.58$459,675.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015Elizabeth H S WyattDirectorSell20,000$28.08$561,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Clive MeanwellCEOSell16,667$30.62$510,343.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Glenn SblendorioCFOSell34,773$30.78$1,070,312.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015William Bernard O'connorSVPSell2,988$28.78$85,994.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014William Bernard O'connorSVPSell2,968$30.31$89,960.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Paul Michael AntinoriVPSell37,883$38.02$1,440,311.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2014William Bernard O'connorSVPSell4,427$39.15$173,317.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/10/2014William Bernard O'connorSVPSell72,384$40.00$2,895,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2014Clive MeanwellCEOSell27,929$38.13$1,064,932.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/3/2014Clive MeanwellCEOSell57,516$38.16$2,194,810.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2013William CrouseDirectorSell12,500$38.00$475,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013Glenn SblendorioCFOSell8,516$38.50$327,866.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013Clive MeanwellCEOSell10,000$36.58$365,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2013Clive MeanwellCEOSell135,000$36.70$4,954,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2013William Bernard O'connorSVPSell6,354$35.00$222,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2013Paul Michael AntinoriVPSell73,500$34.50$2,535,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Clive MeanwellCEOSell7,500$31.85$238,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Clive MeanwellCEOSell7,500$31.26$234,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2013Paul Michael AntinoriVPSell36,000$33.00$1,188,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Clive MeanwellCEOSell7,500$31.25$234,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013Paul Michael AntinoriVPSell109,973$33.29$3,661,001.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2013Armin M KesslerDirectorSell8,750$33.05$289,187.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Glenn SblendorioCFOSell2,709$37.00$100,233.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2013Paul Michael AntinoriVPSell35,000$34.90$1,221,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2013William Bernard O'connorSVPSell29,654$35.00$1,037,890.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for The Medicines (NASDAQ:MDCO)
DateHeadline
07/28/16 01:40 PMAdaptimmune Gets Access To Priority Medicines Regulatory Support For Its SPEAR T-cell Therapy - Adaptimmune Therapeutics plc (Nasdaq: ADAP) revealed Thursday that the European Medicines Agency (EMA) has given permission to access to its newly-established Priority Medicines (PRIME) regulatory initiative for its SPEAR T-cell therapy. According to the company, the drug focuses on NY-ESO for the treatment of HLA-A0201, HLA-A0205, or HLA-A0206 allele positive patients with inoperable or metastatic synovial sarcoma who have got prior chemotherapy and whose tumor expresses the NY-ESO-1 tumor ...Full story available on Benzinga.com
07/28/16 08:19 AMThe Medicines Company (MDCO) Jumps 7.14% on July 27 ... - Equities.com
07/27/16 08:11 PMEdited Transcript of MDCO earnings conference call or presentation 27-Jul-16 12:30pm GMT -
07/27/16 05:27 PMMallinckrodt (MNK) Q3 Earnings: Will the Stock Surprise?
07/27/16 05:27 PMMedicines : posts 2Q profit
07/27/16 06:48 AMThe Medicines Company Reports Second-Quarter 2016 Business and Financial Results - [at noodls] - - Advanced potential blockbuster R&D programs - - Completed divestiture of non-core cardiovascular assets - - Refinanced substantial portion of near-term debt obligations - - Transactions significantly ...
07/27/16 06:36 AMMedicines Co. posts 2Q profit -
07/25/16 09:16 AMMerck Gets Breakthrough Therapy Status From FDA And PRIME Status From EMA For Investigational Ebola Zaire Vaccine - Merck & Co., Inc. (NYSE: MRK) revealed Monday about two regulatory milestones for its investigational vaccine for Ebola Zaire, V920 (rVSV∆G-ZEBOV-GP, live attenuated). While the Food and Drug Administration has granted the vaccine candidate Breakthrough Therapy Status, the European Medicines Agency (EMA) has accorded PRIME (PRIority MEdicines) status. Merck said the FDA's Breakthrough Therapy Designation was planned to expedite the development, as well as review of a candidate that was planned for use, alone or in combination, to treat a serious or life-threatening disease. The company indicated that the candidate could be used when ...Full story available on Benzinga.com
07/22/16 01:45 PMEU watchdog flags faulty generic drug data, backs sales halt - July 22 (Reuters) - The European Medicines Agency (EMA) recommended suspending sales of some generic drugs after a review found that data collected by a contract research company in India for their...
07/21/16 12:25 PMMylan And Biocon Says EMA Accept Its Regulatory Submission Of Biosimilar Pegfilgrastim - Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. revealed that the European Medicines Agency (EMA) has accepted their Marketing Authorization Application (MAA) for their proposed biosimilar Pegfilgrastim for review. The drug is used to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy with the exception of chronic myeloid leukaemia and myelodysplastic syndromes. Mylan and Biocon have co-developed the proposed biosimilar that got the EMA's acceptance of the submission for review. Aside from the ...Full story available on Benzinga.com
07/20/16 05:50 PMThe Medicines Company (NASDAQ:MDCO): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 05:50 PMWere Analysts Bearish The Medicines Company (NASDAQ:MDCO) This Week? - Consumer Eagle
07/20/16 07:14 AMCall buyers targeting Medicines Company -
07/20/16 02:28 AMWatch These 10 Huge Call Purchases In Wednesday Trade - Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Tuesday's regular session. Alibaba Group Holding Ltd (NYSE: BABA) Aug16 85.0 Calls: 3000 @ ASK $1.57: 8215 traded vs 24k OI: Earnings 8/10 $82.33 Ref The Medicines Company (NASDAQ: MDCO) Sep16 38.0 Calls Sweep: 800 @ ASK $2.00: 800 traded vs 0 OI: Earnings 8/3 $34.46 Ref Oclaro, Inc. ...Full story available on Benzinga.com
07/19/16 11:13 AMThe Medicines Company to Announce Second Quarter Financial Results on July 27 ...
07/18/16 05:15 PMAccounts Payable For The Medicines Company (NASDAQ:MDCO) Stood At $15.526 - RealistInvestor.com
07/18/16 10:26 AMTrading Performance and Target Watch for The Medicines Company (NASDAQ:MDCO) - Press Telegraph
07/18/16 10:26 AMEarnings Surprise in Focus: The Medicines Company (NASDAQ:MDCO) - Investor Newswire
07/18/16 07:32 AMBRIEF-EMA classifies Advaxis cervical cancer drug as an 'advanced-therapy medicinal product' - * European Medicines Agency Committee Classifies Advaxis' Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product Source text for Eikon: Further company coverage: (Bengaluru Newsroom...
07/18/16 06:00 AMThe Medicines Company to Announce Second Quarter Financial Results on July 27, 2016 - [Business Wire] - The Medicines Company has scheduled its quarterly conference call for July 27, 2016 at 8:30 a.m. Eastern Time to discuss second quarter financial results and operational developments.
07/17/16 11:31 PMEMA to review Samsung Bioepis Humira biosim application - FiercePharma - FiercePharmaEMA to review Samsung Bioepis Humira biosim applicationFiercePharmaIncheon-based Samsung Bioepis received acceptance for a European Marketing Authorization application for a biosimilar of AbbVie's ($ABBV) blockbuster Humira (adalimumab), which earlier this year was the subject of a legal tussle between the two firms.SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted for Review by European Medicines AgencyBusiness Wire (press release)Samsung Bioepis seeks Europe approval for its Humira copyWHBL Sheboyganall 8 news articles »
07/17/16 09:24 PMUPDATE 1-Samsung Bioepis seeks Europe approval for its Humira copy - * European Medicines Agency reviewing Samsung Bioepis' application
07/17/16 04:38 PMCan The Medicines Company (NASDAQ:MDCO) Surprise Analysts this Quarter? - Investor Newswire
07/17/16 09:25 AMBiotech Battles Bacterial Threats
07/16/16 04:46 PMBridger Management LLC Increased Medicines Co (NASDAQ:MDCO) by $5.73 Million as Shares Declined - Consumer Eagle
07/15/16 09:32 AMLarge Inflow of Money Detected in The Medicines Company - TheFounders Daily
07/14/16 08:43 AMThe Medicines Company (NASDAQ:MDCO) Trading Down - Insiders Are Buying and Selling - Finance Daily
07/12/16 05:22 PMThe Medicines Company Realized Volatility Hits a Dropping Level - CML News
07/12/16 05:22 PMMedicines Co. (MDCO) Affirms Positive Appeals Court Decision in Angiomax Patent Case - StreetInsider.com
07/12/16 09:44 AMAppeals court rules in favor of The Medicines Company in Angiomax patent litigation -
07/12/16 09:29 AMAnalyst's Report Recap: The Medicines Company (NASDAQ:MDCO) - Post Registrar
07/12/16 09:29 AMCompany Shares of The Medicines Company (NASDAQ:MDCO) Rally 2.29% - TheFounders Daily
07/12/16 09:29 AMAnalysis under consideration: The Medicines Company (NASDAQ:MDCO) - News Oracle
07/12/16 09:29 AMMedicines Co. (MDCO): Angiomax Offers Optionality But There's A Real Pipeline and Franchise - RBC - StreetInsider.com
07/12/16 07:33 AMThe Medicines Co. breached its 50 day moving average in a Bullish Manner : MDCO-US : July 12, 2016 -
07/12/16 06:33 AMFederal Circuit Rules for The Medicines Company in Angiomax® (bivalirudin) Patent Litigation - [at noodls] - The Federal Circuit unanimously affirms District Circuit decision on Angiomax patents PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 12, 2016-- The Medicines Company announced that the U.S. Court of Appeals for ...
07/11/16 09:46 AMMedicines Co. (MDCO) Has Suddenly Spiked To The Upside
07/10/16 04:37 PMStock on the Rise for the Quarter: The Medicines Company (NASDAQ:MDCO) - Engelwood Daily
07/10/16 04:37 PMNext Weeks Broker Price Targets For The Medicines Company (NASDAQ:MDCO) - Fiscal Standard
07/08/16 07:59 AMAntipodean Advisors LLC Decreased Stake in Medicines Co (NASDAQ:MDCO) by $31.72 Million as Shares Declined - Engelwood Daily
07/07/16 05:09 PMThe Medicines Company : Announces Positive Top- Line Results for Phase 3 TANGO 1 Clinical Trial of CARBAVANCE®
07/06/16 05:21 PMInsiders Increasing Positions in: The Medicines Company (NASDAQ:MDCO) - Press Telegraph
07/05/16 09:42 AMHow Analysts Rated The Medicines Company (NASDAQ:MDCO) Last Week? - Engelwood Daily
07/04/16 04:35 PMInstitutional Investors Sentiment Indicator of Medicines Co (NASDAQ:MDCO) Increases in Q1 2016 - Press Telegraph
07/02/16 04:51 PMRecently Issued Stock Ratings For The Medicines Company (NASDAQ:MDCO) - Fiscal Standard
06/30/16 08:30 AMThe Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The Medicines and GW Pharma -
06/29/16 01:23 PMBiotech Stock Roundup: Gilead Gets FDA Nod for HCV Drug, Regulus Hit by Clinical Hold -
06/28/16 05:00 PMLeerink Affirms Medicines Company (MDCO) at 'Outperform'; Carbapenem Component Verified w/ Today's Results
06/28/16 09:58 AMThe Medicines Co.'s Carbavance Scores in Phase III Study
06/28/16 09:58 AMMedicines Co.'s (MDCO) CARBAVANCE Phase 3 Met FDA, EMA Primary Endpoints

Social

About The Medicines

The Medicines logoThe Medicines Company is a global biopharmaceutical company. The Company's marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. It sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. It sells over three acute care generic products, including midazolam, ondansetron and rocuronium. The Company's products include Angiomax, which is a direct thrombin inhibitor; Cleviprex, which is a calcium channel blocker; Ionsys, which is a patient-controlled analgesia system; Kengreal, which is an antiplatelet agent; Minocin IV, which is a tetracycline-class antibiotic, and Orbactiv, which is an antibiotic.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: MDCO
  • CUSIP: 58468810
Key Metrics:
  • Previous Close: $38.89
  • 50 Day Moving Average: $35.28
  • 200 Day Moving Average: $34.15
  • P/E Ratio: N/A
  • P/E Growth: -0.11
  • Market Cap: $2.69B
  • Beta: 0.67
  • Current Year EPS Consensus Estimate: $-4.6 EPS
  • Next Year EPS Consensus Estimate: $-3.25 EPS
Additional Links:
The Medicines (NASDAQ:MDCO) Chart for Friday, July, 29, 2016